Skip to content

Bioequivalence study of Famotidine 40 mg coated tablets of Medava Pharmaceutical Company with Famotidine 40 mg coated tablets of Telomed Pharmaceutical Company of England

Bioequivalence study of Famotidine 40 mg coated tablets of Medava Pharmaceutical Company with Famotidine 40 mg coated tablets of Telomed Pharmaceutical Company of England

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT20130313012810N18
Enrollment
24
Registered
2023-11-29
Start date
2023-12-06
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bioequivalence study in healthy volunteers.

Interventions

Intervention 1: Intervention group 1: In this group, volunteers are given a single oral dose of Famotidine tablet 40 mg produced by Modava Co. (Domestic). In each period, 12 of 24 subjects will be giv

Sponsors

Modava Pharmaceutical Company
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: The weight range of participating candidates should be between 60-100 kg Candidates should be healthy in terms of physical examination, ECG and the following laboratory tests: Hemoglobin, Hematocrit, Red and White Blood Count, MCV (Mean Body Volume), MCH (Mean Body Hemoglobin), Routine Urinalysis, Total Cholesterol, Triglyceride, Total Proteins, albumin, uric acid, total bilirubin, alkaline phosphatase, gamma glutamyl transpeptidase (?-GT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), urea, creatinine and fasting blood glucose Volunteers who have agreed to an informed consent form All candidates should not consume caffeine-containing drinks and chocolate during two days before the prescription, and this restriction must be followed until the last blood draw

Exclusion criteria

Exclusion criteria: History of allergic or adverse reaction to Azithromycin or any similar product Volunteers with blood pressure less than 60/90 mm Hg or higher than 90/140 mm Hg Smokers Individuals who donated whole blood or blood components within 2 months within 2 weeks prior to the first dose of the study product(s)

Design outcomes

Primary

MeasureTime frame
Plasma concentration of the drug. Timepoint: 15 sampling time included pre-dose (time 0) and at the following hours post-dose: 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, and 12 h. Method of measurement: Liquid Chromatography with tandem mass spectrometry (LC-MS-MS).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamed Hamishehkar

Tabriz University of Medical Sciences

hamishehkar.hamed@gmail.com+98 41 3336 3181

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026